Tvax Biomedical is a clinical stage drug development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. The company’s lead candidates, focused on treating brain and kidney cancer, are supported by positive phase 2 clinical data and extensive preclinical and phase 1 safety studies. The FDA has authorized the company to initiate pivotal phase 3 clinical trials for both drug candidates to support their potential FDA approval. For further information, visit the company’s Web site at www.tvaxbiomedical.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: